Advertisement

Reactions Weekly

, Volume 1732, Issue 1, pp 4–4 | Cite as

Risk of differentiation syndrome with enasidenib, warns US FDA

News item
  • 22 Downloads

Reference

  1. US Food and Drug Administration. FDA warns that symptoms of a serious condition affecting the blood cells are not being recognized with the leukemia medicine Idhifa (enasidenib). Internet Document : 29 Nov 2018. Available from: URL: https://www.fda.gov/Drugs/DrugSafety/ucm626923.htm

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations